The Automated Molecular Diagnostics Testing System Market is poised for robust growth, with an expected increase from USD 2.5 billion in 2025 to USD 6.1 billion by 2035, marking a compound annual growth rate (CAGR) of 9.2% over the forecast period. This surge in market value is largely driven by the growing demand for rapid, accurate, and high-throughput diagnostic solutions across healthcare systems globally.
Unlock detailed analytics – Request your personalized report now! https://www.futuremarketinsights.com/reports/sample/rep-gb-1506
Key Growth Drivers
The healthcare industry is undergoing a significant shift towards automation to streamline diagnostic processes, reduce errors, and improve efficiency. As the prevalence of infectious diseases, cancer, and genetic disorders rises, healthcare systems worldwide are increasingly adopting automated molecular diagnostics testing systems. These systems offer reliable, scalable, and precise diagnostic results in a fraction of the time required by traditional methods.
Automation in diagnostics has been accelerated by the COVID-19 pandemic, which underscored the need for faster, more accurate testing. The integration of artificial intelligence (AI), robotics, and digital connectivity with molecular diagnostics has further expanded the capabilities of automated systems. Additionally, increasing investments in laboratory modernization and the rise of personalized medicine are expected to support continued market growth.
Segmental Insights
Hardware and Instruments
The hardware and instruments segment is projected to capture the largest share of the market, accounting for 57.8% of the total revenue in 2025. These systems are central to automation in molecular diagnostics, integrating robotics, precision sensors, and high-throughput systems to conduct assays reliably and efficiently. The need for automation in sample preparation, amplification, detection, and data analysis is fueling the demand for advanced instruments.
Oncology Applications
Oncology is expected to remain the leading application area, with a revenue share of 30.5% in 2025. The growing global cancer burden is driving demand for advanced diagnostic systems capable of early detection, staging, and monitoring disease progression. Automated molecular diagnostics systems are playing a key role in identifying genetic mutations and biomarkers, which are critical for personalized cancer treatments. The shift towards companion diagnostics and immunotherapy further strengthens the market’s oncology segment.
Polymerase Chain Reaction (PCR) Technique
The PCR technique is anticipated to dominate the automated molecular diagnostics market, capturing 29.8% of the revenue share in 2025. PCR’s versatility, reliability, and ability to detect a wide range of pathogens, genetic disorders, and oncology-related biomarkers make it the go-to method for molecular diagnostics. Recent advancements in real-time PCR and digital PCR are enhancing its capabilities, further driving market adoption.
Regional Insights
Geographically, North America and Europe are currently the largest markets for automated molecular diagnostics testing systems, driven by high healthcare expenditures, regulatory approval for advanced systems, and widespread adoption of personalized medicine. The U.S. is expected to maintain a steady growth trajectory, with an estimated market value of USD 887.4 million in 2025, reaching USD 1.9 billion by 2035.
The Asia-Pacific (APAC) region is projected to exhibit the highest growth, primarily driven by large research centers in China and India, along with R&D hubs in Japan. The increasing demand for advanced molecular diagnostics in these countries is expected to propel the APAC market over the next decade.
Competitive Landscape
The automated molecular diagnostics testing system market is highly competitive, with several global players leading the charge in innovation and market share. Key players include:
- Roche Holding AG
- Abbott Laboratories
- Becton Dickinson & Company
- Siemens Healthcare GmbH
- Qiagen
- Bio-Rad Laboratories
- Cepheid Inc.
- PerkinElmer Inc.
These companies are focusing on developing scalable, user-friendly, and cost-effective solutions to meet the growing demand for automation in diagnostics. Investments in research and development (R&D) are helping to bring advanced automated systems to market that cater to a wide range of applications, from oncology to infectious disease testing.
Download Brochure for Full Insights: https://www.futuremarketinsights.com/reports/brochure/rep-gb-1506
Challenges and Opportunities
While the market continues to expand, several challenges persist, including the high cost of automated molecular diagnostic systems and the need for highly skilled labor to operate these advanced platforms. However, ongoing technological advancements, including the integration of cloud-based systems for real-time data sharing and decision-making, present significant growth opportunities.
Efforts by companies to develop smaller, more cost-effective, and user-friendly systems will likely accelerate market adoption, particularly in emerging economies where healthcare budgets are limited.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
